X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The CLAROMER drug discovery platform generates a family of novel compounds to precisely target infectious pathogens. CLAROMERS can exhibit improved stability and potency relative to natural peptides and are highly scalable to manufacture.
Lead Product(s): Antimicrobial Peptides
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2022
Details:
The funding will enable Maxwell to accelerate the development of its innovative platform having LL-37, recruit and retain top talent, pursue clinical trials, and scale up manufacturing capabilities.
Lead Product(s): Ropocamptide
Therapeutic Area: Infections and Infectious Diseases Product Name: LL-37
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: DecentraNet
Deal Size: $10.8 million Upfront Cash: Undisclosed
Deal Type: Financing March 10, 2022
Details:
Titled Potent Antiviral Activity against HSV-1 and SARS-CoV-2 by Antimicrobial Peptoids, the research findings demonstrate that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: University of Louisville
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
